AngioDynamics (NASDAQ:ANGO) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Friday, October 19th.
A number of other brokerages have also issued reports on ANGO. Raymond James lowered AngioDynamics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 11th. Canaccord Genuity reissued a “hold” rating and issued a $20.00 target price on shares of AngioDynamics in a research report on Thursday, July 12th. Finally, Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. AngioDynamics has an average rating of “Buy” and a consensus price target of $18.44.
Shares of AngioDynamics stock traded down $0.51 on Friday, hitting $21.38. 107,142 shares of the company were exchanged, compared to its average volume of 162,955. AngioDynamics has a 1-year low of $15.16 and a 1-year high of $24.49. The stock has a market cap of $805.91 million, a P/E ratio of 28.89 and a beta of 0.75. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.64 and a quick ratio of 1.55.
In other news, CFO Michael Greiner sold 1,939 shares of the company’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $21.53, for a total transaction of $41,746.67. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 2.80% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of ANGO. BlackRock Inc. increased its holdings in AngioDynamics by 7.9% in the first quarter. BlackRock Inc. now owns 5,103,954 shares of the medical instruments supplier’s stock valued at $88,045,000 after buying an additional 373,558 shares during the last quarter. New York State Common Retirement Fund boosted its stake in AngioDynamics by 83.4% in the first quarter. New York State Common Retirement Fund now owns 78,947 shares of the medical instruments supplier’s stock valued at $1,362,000 after acquiring an additional 35,900 shares in the last quarter. Principal Financial Group Inc. boosted its stake in AngioDynamics by 2.7% in the first quarter. Principal Financial Group Inc. now owns 298,168 shares of the medical instruments supplier’s stock valued at $5,143,000 after acquiring an additional 7,871 shares in the last quarter. Barclays PLC boosted its stake in AngioDynamics by 238.7% in the first quarter. Barclays PLC now owns 30,769 shares of the medical instruments supplier’s stock valued at $531,000 after acquiring an additional 21,685 shares in the last quarter. Finally, Element Capital Management LLC acquired a new position in AngioDynamics in the first quarter valued at $217,000. 97.54% of the stock is currently owned by hedge funds and other institutional investors.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Read More: Diversification in Your Portfolio
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.